Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Altamira Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of RNA-based therapeutics and delivery technologies. The company operates within the biopharmaceutical and RNA therapeutics industries, with a strategic emphasis on non-viral RNA delivery platforms and intranasal administration routes. Altamira’s core value proposition centers on enabling the safe and effective delivery of RNA therapeutics to extrahepatic tissues, an area that remains a key challenge in the broader RNA drug development landscape.
The company’s primary business activities are driven by its proprietary RNA delivery platform and a limited pipeline of therapeutic candidates, rather than commercialized products. Altamira traces its origins to Auris Medical Holding Ltd., founded in 2003, which initially focused on treatments for ear, nose, and throat disorders. Following multiple clinical setbacks, the company rebranded as Altamira Therapeutics in 2021 and pivoted toward RNA delivery technologies, repositioning itself as a platform-oriented biotechnology company.
Business Operations
Altamira Therapeutics operates as a single-reportable-segment biotechnology company, generating no significant commercial revenue and funding operations primarily through equity financings and strategic transactions. Its core operational focus is the development of the xPhore™ RNA delivery platform, which is designed to enable efficient, non-viral delivery of RNA molecules to tissues outside the liver. The company also maintains legacy therapeutic programs, though these are not currently the primary drivers of strategic focus.
Operations are primarily research- and development-oriented, with activities conducted through a combination of in-house capabilities and external contract research organizations. The company does not operate manufacturing facilities at commercial scale. Altamira has disclosed exploratory collaborations and evaluation agreements related to its delivery technology; however, publicly available information does not confirm material revenue-generating partnerships. Data inconclusive based on available public sources regarding any active joint ventures.
Strategic Position & Investments
Strategically, Altamira Therapeutics is focused on monetizing its RNA delivery technology through out-licensing, research collaborations, and selective internal development. Growth initiatives emphasize demonstrating the versatility of the xPhore™ platform across multiple RNA modalities, including RNA interference and mRNA-based applications. The company has indicated interest in applying its technology to neurological, inflammatory, and rare disease indications.
Altamira has not disclosed any major acquisitions in recent years and instead prioritizes internal platform development. Its investment strategy centers on intellectual property expansion, preclinical validation, and proof-of-concept studies to attract potential pharmaceutical partners. Emerging areas of interest include intranasal and systemic RNA delivery, though clinical-stage validation remains limited based on publicly available filings.
Geographic Footprint
Altamira Therapeutics is headquartered in Switzerland, with its principal executive offices located in Basel. The company is incorporated in Bermuda and listed on the United States public equity markets, reflecting its international corporate structure. Research and administrative activities are primarily concentrated in Europe, while capital markets access and investor relations are largely oriented toward North America.
The company does not report significant physical operations in other regions but maintains a global strategic outlook through intellectual property filings and potential partner engagements. Its market presence is primarily investment- and research-driven rather than commercial, with no disclosed regional revenue concentration.
Leadership & Governance
Altamira Therapeutics was founded under its former corporate identity by Thomas Meyer, who continues to play a central leadership role. The company’s governance structure reflects that of a small, publicly listed biotechnology firm, with a board and executive team overseeing strategy, capital allocation, and scientific direction. Leadership communications emphasize capital discipline, platform validation, and partnership-driven growth.
Key executives disclosed in public filings include:
- Thomas Meyer – Chief Executive Officer
- Christian Wehrli – Chief Financial Officer
Public sources confirm the CEO and CFO roles; information on additional executive appointments is limited or inconsistently reported. Data inconclusive based on available public sources regarding other current executive officers and detailed leadership philosophy statements beyond general strategic disclosures.